Dimensional Fund Advisors LP lowered its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 70.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 35,666 shares of the biotechnology company's stock after selling 86,214 shares during the quarter. Dimensional Fund Advisors LP's holdings in Arrowhead Pharmaceuticals were worth $671,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of ARWR. Norges Bank bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $38,622,000. Edgestream Partners L.P. bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $2,264,000. Wealthfront Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $2,060,000. Marshall Wace LLP bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $1,629,000. Finally, King Luther Capital Management Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $1,447,000. Institutional investors own 62.61% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ARWR. Chardan Capital reissued a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, B. Riley restated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.13.
Check Out Our Latest Stock Report on Arrowhead Pharmaceuticals
Insider Buying and Selling at Arrowhead Pharmaceuticals
In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. The trade was a 1.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 275,880 shares of company stock worth $4,034,037 over the last ninety days. Insiders own 4.30% of the company's stock.
Arrowhead Pharmaceuticals Stock Up 0.5%
ARWR traded up $0.08 during trading on Thursday, reaching $15.39. 1,473,852 shares of the stock were exchanged, compared to its average volume of 1,500,215. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The stock has a market cap of $2.13 billion, a P/E ratio of -2.98 and a beta of 0.89. The stock's 50 day moving average price is $13.32 and its two-hundred day moving average price is $17.70. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the firm earned ($1.02) earnings per share. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.
Arrowhead Pharmaceuticals Company Profile
(
Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
See Also
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
